Clinical-trial halts for futility are common, but halts for actual patient harm are less so. Still, using iHub’s advanced search tool, I’ll bet we could find at least a dozen of them among the posts on this board.
The most famous case was probably PFE’s Torcetrapib.
Market Data 
Markets 
AI
